Disc Medicine
Disc Medicine is seeking an experienced scientist to lead pharmacokinetic and pharmacodynamic studies for both small molecules and biologics within its Drug Metabolism and Pharmacokinetics (DMPK) team. The role involves designing and executing in vitro and in vivo ADME/PK/PD experiments, collaborating with cross‑functional partners, and providing strategic guidance for discovery and development programs.
Disc Medicine is a clinical‑stage biopharmaceutical company focused on developing first‑in‑class therapeutics for hematologic disorders. The company harnesses breakthrough science to translate discoveries into medicines designed to disrupt the current standard of care and improve outcomes for patients and families. Its pipeline includes programs in clinical development and the company works closely with patients, healthcare professionals, investors and partners to advance those therapies. Headquartered in Watertown, Massachusetts, Disc Medicine provides medical, investor and partnership contact channels via its website.
First Light Asset Management LLC Acquires New Holdings in Disc Medicine, Inc. $IRON
15 hours ago
IRON Investors Have Opportunity to Join Disc Medicine, Inc. Fraud Investigation with the Schall Law Firm
2 days ago
FDA rejects rare disease therapy from Disc Medicine, early recipient of commissioner’s voucher
1 month ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Disc Medicine.
12% above the average for this role
US FDA declines to approve Disc Medicine's rare disease drug
1 month ago